Abstract
No public abstract is available from the verified source records.
Mohamed Elsaid, Mai Alaaeldin Temraz Elsebaie, Mayam Mohamed Aziz, Hadeer Sherif, Mohamed H. Mahmoud, Hamsa Hassan, Alaa Soliman
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Eosinophilic gastrointestinal disorders (EGID)
10.1016/j.jaci.2003.10.047 · 2004
Eosinophilic gastrointestinal disorders
10.1007/s12016-019-08732-1 · 2019
Comparison of drugs for active eosinophilic oesophagitis: systematic review and network meta-analysis
10.1136/gutjnl-2023-329873 · 2023
Advances in clinical management of eosinophilic esophagitis
10.1053/j.gastro.2014.07.055 · 2014
Older patients with eosinophilic esophagitis have high treatment response to topical steroids
10.1016/j.dld.2021.10.004 · 2022
Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial
10.1016/j.jaci.2011.11.044 · 2012
Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody
10.2165/11584340-000000000-00000 · 2011
Treatment of patients with the hypereosinophilic syndrome with mepolizumab
10.1056/nejmoa070812 · 2008
Eosinophilic esophagitis in the era of biologics
10.1080/17474124.2024.2374471 · 2024
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
2021
Unresolved referenced work
2026
An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis
10.1053/j.gastro.2011.07.044 · 2011
Benralizumab completely depletes gastrointestinal tissue eosinophils and improves symptoms in eosinophilic gastrointestinal disease
10.1016/j.jaip.2022.02.037 · 2022
Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial
10.1136/gut.2009.178558 · 2010
Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial
10.1136/gutjnl-2023-330337 · 2023
Safety and efficacy of Reslizumab for children and adolescents with Eosinophilic esophagitis treated for 9 years
10.1097/mpg.0000000000001840 · 2018
Eosinophilic esophagitis
10.1016/j.mcna.2018.08.009 · 2019
Prevalence of Eosinophilic gastroenteritis and colitis in a population-based study, from 2012 to 2017
10.1016/j.cgh.2017.05.050 · 2017
Eosinophilic gastritis in children: clinicopathological correlation, disease course, and response to therapy
10.1038/ajg.2014.166 · 2014
Food allergy and eosinophilic esophagitis
10.1097/aci.0b013e328338cbab · 2010
Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome
10.1016/j.jaci.2014.07.026 · 2014
Histopathologic features of eosinophilic esophagitis and eosinophilic gastrointestinal diseases
10.1016/j.gtc.2014.02.007 · 2014
Eosinophilic gastrointestinal disorders pathology
2018
Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference
10.1053/j.gastro.2018.07.009 · 2018
Toxicity of eosinophil MBP is repressed by intracellular crystallization and promoted by extracellular aggregation
10.1016/j.molcel.2015.01.026 · 2015
The eosinophil
10.1146/annurev.immunol.24.021605.090720 · 2006
Oesophageal intrasquamous IgG4 deposits: an adjunctive marker to distinguish eosinophilic oesophagitis from reflux oesophagitis
10.1111/his.12892 · 2016
CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference
2018
Eosinophilic gastrointestinal disorders pathology
2017
Type 2 inflammation in eosinophilic esophagitis: from pathophysiology to therapeutic targets
10.3389/fphys.2021.815842 · 2022
Efficacy of dupilumab in a phase 2 randomized trial of adults with active Eosinophilic esophagitis
10.1053/j.gastro.2019.09.042 · 2020
No additional external references are available.